Neutrophil Oxidative Burst Assay (DHR) 
Ordering Recommendation

Aid in screening for chronic granulomatous disease.

Semi-Quantitative Flow Cytometry
2-3 days
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
ARUP Consult®
Disease Topics
Specimen Required
Patient Preparation
Collect control specimen from a healthy individual unrelated to patient at approximately the same time as and under similar conditions to the patient. 
Green (Sodium or Lithium Heparin) (patient) AND Green (Sodium or Lithium Heparin) (control). Patient and control specimens must be collected within 48 hours of test performance. 
Specimen Preparation
Transport 3 mL whole blood (patient) AND 3 mL whole blood (control) in original collection tubes. (Min: 1 mL (patient) AND 1 mL (control)) Do not refrigerate or freeze. LIVE NEUTROPHILS REQUIRED. 
Storage/Transport Temperature
Unacceptable Conditions
Ambient: 48 hours; Refrigerated: Unacceptable; Frozen: Unacceptable
New York State Clients: Ambient 24 hours; Refrigerated: Unacceptable; Frozen Unacceptable 
Reference Interval
By report
Interpretive Data
White blood cells are incubated with dihydrorhodamine 123 (DHR) and catalase, then stimulated with Phorbol 12-Myristate 13-Acetate (PMA). Dihydrorhodamine oxidation to rhodamine by the respiratory burst of the cell is measured by flow cytometry.

Results are reported as the ratio of the mean channel fluorescence of stimulated cells versus unstimulated cells, which yields a stimulation index (SI).

Compliance Statement B: For laboratory developed tests not using a RUO kit, and for FDA approved, cleared or 510(k) exempt assays with alterations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

If sample shows abnormal results when stimulated, and no control was sent, test should be resubmitted with control sample to validate the conditions of collection, processing and transport.  For abnormal results, we encourage consultation with the ARUP Immunology Medical Director.

Interpretation comparing the patient results to the client normal control and the laboratory control will be provided by the medical director.
Hotline History
View Hotline History
Component Test Code*Component Chart NameLOINC
0096657Neutrophil Oxidative Burst30903-9
2004851EER Neutrophil Oxidative Burst11526-1
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
  • CGD Test
  • Chronic Granulomatous Disease Test
  • DHR test
  • Neutrophil Oxidation